Conmed(NYSE) CNMD

CONMED Corporation makes tools that surgeons use to fix bones. These products help doctors perform operations more safely. The company provides equipment and supplies to surgical centers.

Tools for the Operating Room

• General Surgery: Surgical tools for laparoscopic procedures, smoke evacuation, and cardiac monitoring; accounted for 56% of net sales in the three months ended June 30, 2026.
• Orthopedic Surgery: Implants and instruments used for sports medicine and bone repairs; represented 44% of net sales in the three months ended June 30, 2026.
• Single-use Products: Disposable surgical items used in various procedures; accounted for approximately 86% of net sales.
• Capital Equipment: Large surgical machines like electrosurgical generators and imaging systems that drive recurring sales of related disposable accessories.

Refining the Surgical Portfolio

• Announced the intent to exit gastroenterology product offerings on Dec. 5, 2025, to optimize the business portfolio.
• Terminated a distribution agreement for biliary stents with W.L. Gore & Associates on Jan. 1, 2026.
• Sold various assets related to the gastroenterology business during the first and second quarters of 2026.
• Repurchased $645.2 million in principal value of convertible notes during the quarter ended June 30, 2026.

Global Manufacturing and Reach

CONMED manufactures nearly all its products in facilities located in the United States and Mexico. International sales accounted for 47% of net sales in the six-month period ended June 30, 2026.

A Look at the Books

• Net sales were $343.5 million in the three months ended June 30, 2026, up 0.3% year over year.
• Gross profit margin was 57.5% in the three months ended June 30, 2026, up 250 basis points year over year.
• Net income reached $36.9 million in the six-month period ended June 30, 2026.
• Net cash provided by operating activities was $50.6 million in the six-month period ended June 30, 2026.

The Final Word

CONMED recently exited the gastroenterology market to focus on core surgical and orthopedic products. This shift streamlines operations while maintaining high volumes of recurring revenue through single-use products.